Laser Capture Microdissection Instrument Purchase

描述（由申请人提供）：拟议的项目是获得利用最现代技术进步的设备，以更新我们的激光捕获显微解剖（LCM）设备。LCM是一种从组织切片中分离纯细胞群的技术。可以根据形态学或免疫组织学特征收集细胞。大多数组织甚至肿瘤都是异质的，不同的细胞类型被锁定在形态单位中，与邻近细胞、结缔组织、血管、腺体和肌肉成分、脂肪细胞、炎症细胞或免疫细胞表现出强烈的粘附相互作用。在正常或发育中的器官中，特定的细胞根据内部控制信号、邻近细胞的信号以及激素或生长因子等外部信号表达不同的基因并发生变化。在疾病病理学中，感兴趣的病变细胞，如癌前细胞或侵袭的癌细胞群，被异质组织元素包围。经历类似分子变化的细胞类型，例如那些被认为是疾病进展最确定的细胞类型，可能构成组织活检样本体积的一小部分。因此，来自微解剖细胞的信息更有可能代表其实际组织环境中感兴趣的纯细胞亚群的基因表达的真实模式。这项技术在发育生物学和癌症生物学中特别有用，最近LCM在干细胞生物学的研究中也被证明是有用的（见主要用户Dennis Roop的项目）。2004年，我们通过癌症中心病理核心共享资源设施建立了LCM服务。我们描述了该仪器在我们机构的几个关键用户的研究，以及我们癌症中心成员更广泛的使用。威尔伯·富兰克林博士将担任咨询委员会主席，负责有效、公平地使用该系统。Jennifer Richer博士将负责设备的日常操作和维护以及用户培训。由于癌症中心病理核心的基础设施已经到位，并且一群才华横溢、富有成效的研究人员现在使用旧版本的激光捕获显微解剖仪器，因此可以保证有效使用。公共卫生相关性：

DESCRIPTION (provided by applicant): The proposed project is to obtain equipment that utilizes the most modern technological advances in order to update our laser capture microdissection (LCM) equipment. LCM is a technology for isolating pure populations of cells from tissue sections. Cells can be collected based on morphologic or immunohistologic features. Most tissues or even tumors are heterogeneous with different cell types locked in morphologic units exhibiting strong adhesive interactions with adjacent cells, connective stroma, blood vessels, glandular and muscle components, adipose cells, and inflammatory or immune cells. In normal or developing organs, specific cells express different genes and undergo changes according to internal control signals, signals from adjacent cells, and external signals such as hormones or growth factors. In disease pathologies, the diseased cells of interest, such as pre- cancerous cells or invading groups of cancer cells, are surrounded by heterogeneous tissue elements. Cell types undergoing similar molecular changes, such as those thought to be most definitive of the disease progression, may constitute a minority of the volume of the tissue biopsy sample. Information from microdissected cells is therefore more likely to represent the true pattern of gene expression of the pure cell subpopulations of interest in their actual tissue context. This technology has been particularly useful in developmental biology and cancer biology, and recently LCM has also proven instrumental in the study of stem cell biology (see project of major user Dennis Roop). We established LCM as a service offered via our Cancer Center Pathology Core Shared Resource Facility in 2004. We describe the research of several key users of the instrument at our institution as well as a broader use by members of our Cancer Center. Dr. Wilbur Franklin will chair the Advisory Committee responsible for productive, efficient and equitable use of the system. Dr. Jennifer Richer will be responsible for the day-to-day operation and maintenance of the equipment and user training. Productive use will be assured because of the infrastructure of the Cancer Center Pathology Core already in place and a talented and productive group of researchers that now utilize the older version of laser capture microdissection instrumentation. PUBLIC HEALTH RELEVANCE: The proposed project is to obtain equipment that represents the most modern technological advances to update our laser capture microdissection (LCM) capabilities. LCM is a technology for isolating pure populations of cells of interest from mixed populations. This technology is not only important for understanding normal developmental biology, but also numerous diseases including cancer.